Since inception, the company has been well focused on what was needed for the patients, doctors and payers and has produced a superior product.Medical device development from inception to market cost on average about $94 million; Guided Therapeutics has spent approximately $40 million on the LuViva development program of which half has been non-dilutive.
This is a pivotal year for Guided Therapeutics, a company few have heard of because of its microcap status and bulletin board listing. Current valuation in no way represents the trajectory of the company in the near and longer term. LuViva is a superior product that will disrupt the cervical cancer screening market and provide screening in new markets. Once acceptance of the product in the market place is assured, Guided Therapeutics will be a very attractive acquisition with large addressable markets, a rich pipeline, little competition and strong intellectual property. Building an early position ahead of near term catalysts outweighs the risk of a small capital raise. For those with longer-term horizons this could be a little gem.
FIGGY thank you for the thumbs down on my post here, from you it's quite a compliment! I am putting you on Ignore and I hope no one replies to your nonsense again so I don't have to be pestered by it. You act like a stupid 8 year old. Enjoy your life.
Good Morning Uncle T,
Wish could give ten thumb up but only allowed one.
Figgy is misguided. To be honest, you probably made him money by stopping him from unloading the rest of his shares. Down the road, when he profits I hope he'll be honest and thank you.